CEBPZ and acute myeloid leukemia: The ability to monitor molecular MRD with transcript specific qRTPCR allows accurate assessment of remission status and prediction of impending morphological relapse in CBF‐AML as has been shown in the UK MRC AML 15 trial and by other groups.12, 33